Cargando…

Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020

BACKGROUND: The updated estimates of hepatitis C virus (HCV) seroprevalence are critical for developing strategies to manage or eliminate HCV infection. METHODS: A comprehensive study on HCV seroprevalence was conducted among 365,210 patients at Jinan Central Hospital, China, from 2008 to 2020. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Mingjie, Liu, Fang, Zhao, Qianqian, Zhou, Yunying, Zhuang, Yuanmei, Ji, Mingyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997000/
https://www.ncbi.nlm.nih.gov/pubmed/36894961
http://dx.doi.org/10.1186/s40001-023-01063-0
_version_ 1784903169421082624
author Xu, Mingjie
Liu, Fang
Zhao, Qianqian
Zhou, Yunying
Zhuang, Yuanmei
Ji, Mingyu
author_facet Xu, Mingjie
Liu, Fang
Zhao, Qianqian
Zhou, Yunying
Zhuang, Yuanmei
Ji, Mingyu
author_sort Xu, Mingjie
collection PubMed
description BACKGROUND: The updated estimates of hepatitis C virus (HCV) seroprevalence are critical for developing strategies to manage or eliminate HCV infection. METHODS: A comprehensive study on HCV seroprevalence was conducted among 365,210 patients at Jinan Central Hospital, China, from 2008 to 2020. The patients were tested for anti-HCV, HCV core antigen, hepatitis B surface antigen, syphilis antibody, human immunodeficiency virus antigen + antibody, antihepatitis A virus IgM, and antihepatitis E virus IgM. RESULTS: HCV seroprevalence was 0.79% and was related to age. HCV seropositivity was lower in children (aged  < 18 years) than in adults (aged  ≥ 18 years) (0.15% vs. 0.81%). High HCV prevalence was reported in adults aged  ≥ 41 years, and HCV seropositivity in those aged 41–80 years accounted for 74.56% of all seropositive individuals. Notably, the rate of HCV–HIV coinfection was 0. HCV seroprevalence was considerably higher in patients at the Kidney Disease Unit and Dialysis Department than in those at other departments (inpatient or outpatient). CONCLUSIONS: HCV seroprevalence was lower in Jinan region but higher in patients at the Kidney Disease Unit and Dialysis Department, especially in those undergoing hemodialysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01063-0.
format Online
Article
Text
id pubmed-9997000
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99970002023-03-10 Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020 Xu, Mingjie Liu, Fang Zhao, Qianqian Zhou, Yunying Zhuang, Yuanmei Ji, Mingyu Eur J Med Res Research BACKGROUND: The updated estimates of hepatitis C virus (HCV) seroprevalence are critical for developing strategies to manage or eliminate HCV infection. METHODS: A comprehensive study on HCV seroprevalence was conducted among 365,210 patients at Jinan Central Hospital, China, from 2008 to 2020. The patients were tested for anti-HCV, HCV core antigen, hepatitis B surface antigen, syphilis antibody, human immunodeficiency virus antigen + antibody, antihepatitis A virus IgM, and antihepatitis E virus IgM. RESULTS: HCV seroprevalence was 0.79% and was related to age. HCV seropositivity was lower in children (aged  < 18 years) than in adults (aged  ≥ 18 years) (0.15% vs. 0.81%). High HCV prevalence was reported in adults aged  ≥ 41 years, and HCV seropositivity in those aged 41–80 years accounted for 74.56% of all seropositive individuals. Notably, the rate of HCV–HIV coinfection was 0. HCV seroprevalence was considerably higher in patients at the Kidney Disease Unit and Dialysis Department than in those at other departments (inpatient or outpatient). CONCLUSIONS: HCV seroprevalence was lower in Jinan region but higher in patients at the Kidney Disease Unit and Dialysis Department, especially in those undergoing hemodialysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01063-0. BioMed Central 2023-03-09 /pmc/articles/PMC9997000/ /pubmed/36894961 http://dx.doi.org/10.1186/s40001-023-01063-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Mingjie
Liu, Fang
Zhao, Qianqian
Zhou, Yunying
Zhuang, Yuanmei
Ji, Mingyu
Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020
title Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020
title_full Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020
title_fullStr Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020
title_full_unstemmed Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020
title_short Seroprevalence of hepatitis C virus in Jinan, China, 2008–2020
title_sort seroprevalence of hepatitis c virus in jinan, china, 2008–2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997000/
https://www.ncbi.nlm.nih.gov/pubmed/36894961
http://dx.doi.org/10.1186/s40001-023-01063-0
work_keys_str_mv AT xumingjie seroprevalenceofhepatitiscvirusinjinanchina20082020
AT liufang seroprevalenceofhepatitiscvirusinjinanchina20082020
AT zhaoqianqian seroprevalenceofhepatitiscvirusinjinanchina20082020
AT zhouyunying seroprevalenceofhepatitiscvirusinjinanchina20082020
AT zhuangyuanmei seroprevalenceofhepatitiscvirusinjinanchina20082020
AT jimingyu seroprevalenceofhepatitiscvirusinjinanchina20082020